Health Care · Laboratory Analytical Instruments · Nasdaq · CIK 1162194 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.87Day +9.97%Mkt cap $341M1Y −37.1%Off 52W high −49.2%Vol (1Y) 68.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,139 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.6% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)−0.82% |
| Top-10 13F concentration84.6% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$86.3M |
| Earnings (TTM)$78.2M |
| ROE−16.7% |
| Net margin−87.8% |
| ROIC−28.6% |
| Sales growth 3Y−4.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−31.7% |
| 1Y−37.1% |
| 3Y−64.3% |
| 5Y−56.1% |
| 10Y−56.1% |
| Since incept. (ann.)−9.3% |
Total return through 2026-07-29 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)68.7% |
| Ann. volatility (3Y)76.6% |
| Sharpe (1Y)−0.36 |
| Sharpe (3Y)−0.05 |
| Max drawdown (1Y)−56.5% |
| Max drawdown (3Y)−76.1% |
| Beta (3Y vs SPY)1.23 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Casdin Capital, LLC | 88.8M | $82M | 22.76% | +0.0% |
| VIKING GLOBAL INVESTORS LP | 58.7M | $54M | 15.04% | +0.0% |
| MAK CAPITAL ONE LLC | 26.2M | $24M | 6.71% | +35.7% |
| BlackRock, Inc. | 24.8M | $23M | 6.35% | −3.0% |
| Long Focus Capital Management, LLC | 16.0M | $15M | 4.11% | +26.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 12.8M | $12M | 3.29% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 7.3M | $7M | 1.87% | −1.8% |
| STATE STREET CORP | 6.6M | $6M | 1.68% | +1.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $0.33 | — | $21.1M | +4.6% |
| 2025-12-31 | 2026-02-24 | — | — | $23.8M | +2573.6% |
| 2025-09-30 | 2025-11-04 | −$0.09 | — | $19.6M | −11.5% |
| 2025-06-30 | 2025-08-11 | −$0.09 | — | $21.8M | −3.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
EMEA 42% · Americas 36% · Asia Pacific 22%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
